S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine (2014/6/14)|
|Sanofi: Solid Sales and Business EPS Growth at CER|
|Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering than Liraglutide when Both were Added to Insulin Glargine (2014/6/14)|
|FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo®|
|Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission|
|Sanofi Canada launching YouTube Channel (2014/9/9)|
|Sanofi Launches Authorized Generic Version of Eloxatin® (oxaliplatin injection) (2014/8/12)|
|Sanofi Announces $2.5 Million Contribution to Dementia Research|
|Sanofi Announces Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) in Japanese People with Uncontrolled Diabetes (2014/6/14)|
|Sanofi Trial Vaccine Effective Against Dengue, Study Finds (2014/9/3)|
Click above to view more mutual fund data and stats for sny - Sanofi ADR.